UNSPSC 51182209: Deaminooxytocin or demoxytocin

This classification denotes an oxytocin analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N9HM3X95F. European Medicines Agency schedules Demoxytocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06971MIG. Demoxytocin generally arises in the molecular formula C43H65N11O12S2.

The term DEMOXYTOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) DEMOXYTOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Deaminooxytocin or demoxytocin bears US NLM identifiers UMLS ID C0057218 and NCI Concept Code C96860. SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.

UNSPSC 51182209 Deaminooxytocin or demoxytocin is a Commodity code covering pharmaceutical products distributed through state and local government cooperative purchasing. State and local governments procure generic pharmaceuticals and over-the-counter products under this code through multistate cooperative agreements administered by state procurement offices. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a primary issuing body for this category, managing agreements that span multiple participating states and local government facilities. Vendors supplying under this code must meet stringent compliance requirements including current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with authorized pharmaceutical wholesalers, and carry comprehensive insurance coverage including $5 million commercial general liability per occurrence. Products must comply with FDA requirements, possess expiration dates of at least one year from manufacture, and maintain a minimum six-month shelf life.

MMCAP's January 2026 Request for Proposal for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, represents the primary recent activity under this code. The solicitation seeks multiple contract awards for comprehensive pharmaceutical distribution across participating states including Oregon, with pricing evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing stability, and the remainder on administrative compliance including EDI capability and agreement to a 3 percent administrative fee. Vendors must distribute products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with resulting contracts effective July 1, 2026. The RFP identifies no specific set-aside restrictions, and contract terms extend two years for new vendors with optional extensions at MMCAP's discretion.